Compare peptides side-by-side
Pick any two peptides to compare their evidence quality, FDA approval status, research scores, risks, and indications. All data sourced from the SmartPeptide library.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
Semaglutide
GLP-1 receptor agonist with extensive Phase 3 trial data for type 2 diabetes and chronic weight management. Prescription-only in most jurisdictions.
Full pageStrong Phase 3 evidence (STEP 1–8 trials). STEP-1 (n=1,961) showed ~14.9% body-weight reduction at 68 weeks vs ~2.4% placebo. SELECT trial (n=17,604) showed reduced major adverse cardiovascular events in overweight/obese adults without diabetes.
Long-term effects beyond ~3–4 years of continuous use, optimal dosing for weight maintenance after stopping, and use in lean populations remain active research areas.
Pancreatitis risk, gallbladder events, contraindicated in personal/family history of medullary thyroid carcinoma.
Nausea, GI upset, constipation, fatigue. Discuss with a licensed prescriber.
Tirzepatide
Dual GIP / GLP-1 receptor agonist with strong Phase 3 evidence in type 2 diabetes (SURPASS) and obesity (SURMOUNT).
Full pageSURMOUNT-1 (n=2,539) showed up to ~22.5% body-weight reduction at 72 weeks at the 15 mg dose. SURPASS trials demonstrated robust HbA1c improvement vs comparators in type 2 diabetes.
Direct head-to-head with semaglutide for cardiovascular outcomes is still maturing. Long-term durability of weight loss after discontinuation remains under study.
Similar profile to GLP-1 agonists. Prescription-only.
GI side effects, injection-site reactions.